Comparative evaluation of immunotherapeutic efficacy of BCG and Mw vaccines in patients of borderline lepromatous and lepromatous leprosy

International Journal of Leprosy and Other Mycobacterial Diseases

Volumn 73, Issue 2, 2005, Pages 105-114

  Narang, Tarun ^a   Kaur, Inderjeet ^a   Kumar, Bhushan ^a   Radotra, Bishan Dass ^a   Dogra, Sunil ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; LEPROSTATIC AGENT; MYCOBACTERIUM W VACCINE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COUNT; BORDERLINE LEPROSY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; LEPROMATOUS LEPROSY; MALE; MYCOBACTERIUM LEPRAE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADOLESCENT; ADULT; BACTERIAL VACCINES; BCG VACCINE; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY, BORDERLINE; LEPROSY, LEPROMATOUS; MALE; MYCOBACTERIUM LEPRAE; RECURRENCE;

EID: 33745934915     PISSN: 0148916X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. AMENU, A., SAUNDERSON, P., DESTA, K., and BYASS, P. The pattern of decline in bacillary index after 2 years of W.H.O. recommended multiple drug therapy: the AMFES cohort. Lepr. Rev. 71 (2000) 332-337.
2. BECHELLI, L. M., LWIN, K., GARBAJOSA, G., GYIMM, VEMARA, K., and SUNDARAM, T. BCG vaccination of children against Leprosy: 9 year findings of the controlled WHO trial in Burma. Bull. W.H.O. 51 (1974) 93-99.
3. BHATKI, W. S., and CHULAWALA, R. G. Immunotherapeutic potential of ICRC vaccine: a case control study. Lepr. Rev. 63 (1992) 358-364.
4. BRANDSMA, J.W., DE JONG, N., and TJEPKEMA, T. Disability grading in leprosy; suggested modification to WHO disability grading form. Lepr. Rev. 57 (1986) 361-369.
5. BULLETIN OF THE LEPROSY ELIMINATION ALLIANCE. Volume 1, No. 4, Oct. to Dec. 2003.
6. CELLONA, R. V., BALAGON, M. F.,DELA, CRUZ, E. C., BURGOS, J. A., ABALOS, R. M., WALSH, G. P., TOPOLSKI, R., GELBER, R. H., and WALSH, D. S. Long-term efficacy of 2 year W.H.O. multiple drug therapy (M.D.T.) in multibacillary (MB) leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 71 (2003) 308-319.
7. CONVIT, J., ARANZAZU, N., ULRICH, M., PINARDI. M.E., REYES, O., and ALVARADO, J. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda negative contacts. Int. J. Lepr. Other Mycobact. Dis. 50 (1982) 415-424.
8. CREE, I. A., MCDOUGALL, A. C., COGHILL, G., and BECK, J. S. Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Int. J. Lepr. Other Mycobact. Dis. 53 (1985) 582-586.
9. DE SARKAR, A., KAUR, I., RADOTRA, B. D., and KUMAR, B. Impact of combined Mycobacterium w vaccine and 1 year of M.D.T. on multibacillary leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 69 (2001) 187-194.
10. DHARMENDRA. Classification of Leprosy. Leprosy, 2nd edn. Edinburgh: Churchill Livingstone, 1994. 179-190.
11. GIRDHAR, B. K., GIRDHAR, A., and KUMAR, A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr. Rev. 71 (2000) 144-153.
12. IYER, C. G. S., BALKRISHNAN, S., and RAMU, G. A comparison of low and conventional dosages of dapsone in the treatment of lepromatous leprosy in India. Lepr. India 49 (1977) 372-388.
13. KAPLAN, G., BRITTON, W. J., HANCOCK, G. E., THEUVENET, W. J., SMITH, K. A., JOB, C. K., ROCHE, P. W., MOLLOY, A., BURKHARDT, R., and BARKER, J. The systemic influence of recombinant interleukin-2 on the manifestations of lepromatous leprosy. J. Exp. Med. 173 (1991) 993-1006.
14. KAR, H., SHARMA, A. K., MISRA, R. S., BEENA, K. R., ZAHEER, S. A., MUKHERJEE, R., MUKHERJEE, A., PARIDA, S. K., WALIA, R., NAIR, S. K., and TALWAR, G. P. Reversal reactions in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate antileprosy vaccine, Mycobacterium w. Lepr. Rev. 64 (1993) 219-226.
15. KAUR, I., DOGRA, S., KUMAR, B., and RADOTRA, B. D. Combined 12-month W.H.O./M.D.T. MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients. Int. J. Lepr. Other Mycobact. Dis. 70 (2002) 174-181.
16. KATOCH, K., KATOCH, V. M., NATRAJAN, M., BHATIA, A. S., SREEVATSA, GUPTA, U. D., SHARMA, V. D., SHIVANNAVAR, C. T., PATIL, M. A., and BHARDWAJ, V. P. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Int. J. Lepr. Other Mycobact. Dis. 63 (1995) 102-111.
17. KUMAR, B., DOGRA, S., and KAUR, I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int. J. Lepr. Other Mycobact. Dis. 72 (2004) 125-133.
18. KUMAR, R. H., KUMAR, M. V., and THAPPA, D. M. Dapsone syndrome - a five year retrospective analysis. Indian J. Lepr. 70 (1998) 271-276.
19. LEMASTER, J. W., SHWE, T., BUTLIN, C. R., and ROCHE, P. W. Prediction of "highly skin smear positive" cases among MB leprosy patients using clinical parameters. Lepr. Rev. 72 (2001) 23-28.
20. LOCKWOOD, D. N. J., VINAYAKUMAR, S., STANLEY, J. N. A., MCADAM, P. W. J., and COLSTON, M. J. Clinical features and outcome of reversal (type 1) reactions in Hyderabad. India. Int. J. Lepr. Other Mycobact. Dis. 61 (1993) 8-15.
21. MARCHOUX CHEMOTHERAPY STUDY GROUP. Relapses in multibacillary leprosy patients after stopping treatment with rifampicin containing combined regimens. Int. J. Lepr. Other Mycobact. Dis. 60 (1992) 525-535.
22. MATHUR, N. K., MITTAL, A., MATHUR, D., and JAIN, S. K. Long-term follow-up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Int. J. Lepr. Other Mycobact. Dis. 60 (1992) 98-100.
23. MUKHERJEE, A., ZAHEER, S. A., SHARMA, A. K., MISRA, R. S., KAR, H. K., MUKHERJEE, R., and TALWAR, G. P. Histopathological monitoring of immunotherapeutic trial with Mycobacterium w. Int. J. Lepr. Other Mycobact. Dis. 60 (1992) 28-35.
24. RAO, P. N., and LAKSHMI, T. S. Increase in the incidence of dapsone hypersensitivity syndrome-an appraisal. Lepr. Rev. 72 (2001) 57-62.
25. SCOLLLARD, D. M., SMITH, T., BHOOPAT, L., THEETRANONT, C., RANGDAENG, S., and MORENS, D. M. Epidemiologic characteristics of leprosy reactions. Int. J. Lepr. Other Mycobact. Dis. 62 (1994) 559-567.
26. SENGUPTA, U. Immunopathology of leprosy; a state of the art. Int. J. Lepr. Other Mycobact. Dis. 69 (2001) S36-S41.
27. SHARMA, P., KAR, H. K., MISRA, R. S., MUKHERJEE, A., KAUR, H., MUKHERJEE, R., and RANI, R. Reactional states and neuritis in multibacillary leprosy patients following MDT with/ without immunotherapy Mycobacterium w vaccine. Lepr. Rev. 71 (2000) 193-205.
28. SHARMA, P., KAR, H. K., MISRA, R. S., MUKERJEE, R., and RANI, R. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine. Int. J. Lepr. Other Mycobact. Dis. 67 (1999) 250-258.
29. STANLEY, S. I., HOWLAND, C., STONE, M. M., and SUTHERLAND, I. BCG vaccination against leprosy in Uganda: final results. J. Hyg. (Camb.) 87 (1981) 233-248.
30. TALWAR, G. P, ZAHEER, S. A., MUKHERJEE, R., WALIA, R., MISRA, R. S., SHARMA, A. K., KAR, H. K., MUKERJEE, K., PARIDA, S. K., SURESH, N. R., NAIR, S. K., and PANDEY, R. M. Immunotherapeutic effects of vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w, in multibacillary leprosy patients. Vaccine 8 (1990) 121-129.
31. VAN BRAKEL, W. H.,DE SOLDENHOFF, R., and MCDOUGALL, A. C. The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. Lepr. Rev. 63 (1992) 231-246.
32. VAN BRAKEL, W., KIST, P., NOBLE, S., and O'TOOLE, L. Relapses after multidrug therapy: a preliminary report of 22 cases in West Nepal. Lepr. Rev. 60 (1989) 45-50.
33. WALIA, R., SARATH CHANDRA, K. G., PANDEY, R. M., PARIDA, S. K., ZAHEER, S. A., and KAR, H. K. Field trials on the use of Mycobacterium w vaccine in conjunction with multidrug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes. Lepr. Rev. 64 (1993) 302-311.
34. W.H.O. EXPERT COMMITTEE ON LEPROSY. Seventh Report. Geneva: World Health Organization, 1998. Tech. Rep. Ser. No. 874.
35. ZAHEER, S. A., BEENA, K. R., KAR, H. K., SHARMA, A. K., MISRA, R. S., MUKHERJEE, A., MUKHERJEE, R., KAUR, H., PANDEY, R. M., WALIA, R., MUKHOPADHYAY, and TALWAR, G. P. Addition of immunotherapy with Mycobacterium w vaccine to M.D.T. benefits multibacillary leprosy patients. Vaccine 13 (1995) 1102-1110.